A panel of experts on multiple myeloma review a patient profile, offer their initial impressions, and highlight the role of an advanced practice provider.
Relapsed/Refractory Multiple Myeloma Treatment Decision Making
Focusing on patient education, the panel outlines resources available to help patients with multiple myeloma navigate their treatment journey.
Turning the focus back to the clinical scenario, Donna Catamero, ANP-BC, OCN, CCRC, discusses the patient’s repeat diagnostic workup and the panel provides their insights on treatment decisions.
Clinical insights on treatment sequencing and the role of talquetamab, highlighting its safety profile in patients with multiple myeloma.
Expert perspectives on educating patients with multiple myeloma on adverse effects related to treatment with talquetamab.
Comprehensive insights on the management of toxicities seen in patients with multiple myeloma who are receiving talquetamab.
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
Tiffany Richards, PhD, ANP-BC, and the rest of the panel offer clinical advice on the care of patients with multiple myeloma who are receiving talquetamab.
The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
5